相关实验视频

Updated: Jun 13, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

多发性硬化症中二次进展的标记物

André Bastos¹, Mafalda Soares², Joana Guimarães³

¹Faculty of Medicine of University of Porto, Porto, Portugal.

Multiple sclerosis and related disorders

|September 15, 2024

概括

由于缺乏明确的标准,诊断次级渐进性多发性硬化症 (SPMS) 是一个挑战. 本综述确定了关键生物标志物,如认知变化和质标志物,这些生物标志物可能有助于更早地检测和管理SPMS.

科学领域:

神经学神经学
生物标志物发现发现
疾病的进展疾病的进展

背景情况:

二次渐进性多发性硬化症 (SPMS) 缺乏普遍接受的定义或诊断标准.
SPMS诊断往往是追溯和延迟的,阻碍了及时的干预.

研究的目的:

审查当前对多发性硬化症 (MS) 现型变化的理解.
从可用的文献中确定用于检测过渡到SPMS的见解和生物标志物.

主要方法:

进行了全面的文献审查,重点是从复发性转移性多发性硬化 (RRMS) 过渡到SPMS.
在多个数据库中搜索了针对SPMS的诊断工具和生物标志物的研究.

主要成果:

包括过去二十年的62项研究;EDSS-plus对残疾进展的敏感性比EDSS更高.
识别了认知障碍 (工作记忆,处理速度,口语流),缓慢扩展的MRI病变和视网膜层稀释 (OCT) 作为诊断指标.
质标记物 (GFAP,CHI3L1) 可能比NfL更适合用于识别转化为进展性疾病;需要对患者报告结果措施 (PROMs) 进行进一步的研究.

结论:

新兴的生物标志物包括认知障碍,MRI发现和质标志物在早期发现SPMS方面显示出有前途.
了解这些生物标志物的进展对于彻底改变SPMS诊断和临床管理至关重要.

关键词:

诊断诊断诊断诊断诊断多发性硬化症是多发性硬化症.一个进步的进步.

更多相关视频

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...